Risk factors associated with complications and mortality in patients with clostridium difficile infection

Clinical Infectious Diseases

Volumn 53, Issue 12, 2011, Pages 1173-1178

  Morrison, Rosemary H ^a   Hall, Natalie S ^b   Said, Mina ^b   Rice, Tamar ^b   Groff, Harold ^c   Brodine, Stephanie K ^a   Slymen, Donald ^a   Lederman, Edith R ^a,c,d  

^a SAN DIEGO STATE UNIVERSITY   (United States)

^b Pharmacy Department   (United States)

^c NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CHILD; CLOSTRIDIUM DIFFICILE INFECTION; DEATH; FEMALE; HOSPITAL ADMISSION; HUMAN; INFANT; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MEGACOLON; MORTALITY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS; INFANT; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 81855160864     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir668     Document Type: Article

References (22)

1. Redelings M, Sorvillo F, Mascola L. Increase in Clostridium difficilerelated mortality rates, United States, 1999-2004. Emerg Infect Dis 2007; 13:1417-9. (Pubitemid 47510317)
2. Centers for Disease Control and Prevention. Severe Clostridium difficile-associated disease in populations previously at low risk-four states, 2005. Morb Mortal Wkly Rep 2005; 54:1201-5.
3. Tan ET, Robertson CA, Brynildsen S, Bresnitz E, Tan C, McDonald C. Clostridium difficile-associated disease in New Jersey hospitals, 2000-2004. Emerg Infect Dis 2007; 13:498-500. (Pubitemid 46348144)
4. Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010; 170:784-90.
5. Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med 2010; 170:772-8.
6. Katz MH. Failing the acid test: benefits of proton pump inhibitors may not justify the risks for many users. Arch Intern Med 2010; 170:747-8.
7. DuPont HL, Garey K, Caeiro JP, Jiang ZD. New advances in Clostridium difficile infection: changing epidemiology, diagnosis, treatment and control. Curr Opin Infect Dis 2008; 21:500-7.
8. Greenstein AJ, Byrn JC, Zhang LP, Swedish KA, Jahn AE, Divino CM. Risk factors for the development of fulminant Clostridium difficile colitis. Surgery 2008; 143:623-9.
9. Kelly CP, LaMont JT. Clostridium difficile-more difficult than ever. N Engl J Med 2008; 359:1932-40.
10. McFarland LV. Renewed interest in a difficult disease: Clostridium difficile infections-epidemiology and current treatment strategies. Curr Opin Gastroenterol 2008; 25:24-35.
11. Pepin J, Valiquette L, Alary M, et al. Clostridium difficile associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171:466-71.
12. Cober ED, Malani PN. Clostridium difficile infection in the "oldest" old: clinical outcomes in patients aged 80 and older. J Am Geriatr Soc 2009; 57:659-62.
13. McFarland LV, Clarridge JE, Beneda HW, Raugi GJ. Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration Health Care System. Clin Infect Dis 2007; 45:1141-51. (Pubitemid 47580312)
14. Dial S, Delaney J, Barkun A, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficileassociated disease. JAMA 2005; 294:2989-95. (Pubitemid 41817660)
15. Peled N, Pitlik S, Samra Z, Kazakov A, Bloch Y, Bishara J. Predicting Clostridium difficile toxin in hospitalized patients with antibioticassociated diarrhea. Infect Control Hosp Epidemiol 2007; 28:377-81. (Pubitemid 46658048)
16. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007; 102:2047-56. (Pubitemid 47301504)
17. Hardt C, Berns T, Treder W, Dumoulin FL. Univariate and multivariate analysis of risk factors for severe Clostridium difficile-associated diarrhea: importance of co-morbidity and serum C-reactive protein. World J Gastroenterol 2008; 14:4338-41.
18. Nachnani JS, Bulchandani D, Allen MJ. Proton pump inhibitors are an independent risk factor for an increased length of hospital stay in patients with Clostridium difficile infection. Indian J Gastroenterol 2008; 27:171-2.
19. Siemann M, Koch-Dörfler M, Rabenhorst G. Clostridium difficileassociated diseases. The clinical courses of 18 fatal cases. Intensive Care Med 2000; 26:416-21. (Pubitemid 30301522)
20. Barbut F, Decré D, Lalande V, et al. Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actin-specific ADPribosyltransferase)-producing strain. J MedMicrobiol 2005; 54:181-5. (Pubitemid 40868005)
21. Carroll KC. Tests for the diagnosis of C. difficile infection: the next generation. Anaerobe 2011; 17:170-4.
22. Karas JA, Enoch DA, Aliyu SH. A review of mortality due to Clostridium difficile infection. J Infect 2010; 61:1-8.